You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Details for Patent: 9,474,779


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,474,779
Patent landscape, scope, and claims:
Title:Therapeutically active compositions and their methods of use
Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
Inventor(s): Lemieux; Rene M. (Newtown, CT), Popovici-Muller; Janeta (Waltham, MA), Travins; Jeremy (Southborough, MA), Cai; Zhenwei (Belle Mead, NJ), Cui; Dawei (Shanghai, CN), Zhou; Ding (Shanghai, CN)
Assignee: Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/745,005
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,474,779

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes 9,474,779 ⤷  Subscribe Y Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ⤷  Subscribe
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes 9,474,779 ⤷  Subscribe Y Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) ⤷  Subscribe
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes 9,474,779 ⤷  Subscribe Y Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML) ⤷  Subscribe
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes 9,474,779 ⤷  Subscribe Y Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES ⤷  Subscribe
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes 9,474,779 ⤷  Subscribe Y Y A METHOD FOR TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WITH IVOSIDENIB IN COMBINATION WITH AZACITIDINE WHEREIN THE CANCER IS NEWLY DIAGNOSED AML ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,474,779

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2804851 ⤷  Subscribe 301243 Netherlands ⤷  Subscribe
European Patent Office 2804851 ⤷  Subscribe CA 2023 00025 Denmark ⤷  Subscribe
European Patent Office 2804851 ⤷  Subscribe LUC00315 Luxembourg ⤷  Subscribe
European Patent Office 2804851 ⤷  Subscribe PA2023529 Lithuania ⤷  Subscribe
European Patent Office 2804851 ⤷  Subscribe 30/2023 Austria ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.